Crucell N.V. (CRXL) Announces PER.C6(R) Licensing Agreement with Acambis (ACAM)
11/20/2007 4:05:33 PM
LEIDEN, NETHERLANDS--(Marketwire - November 20, 2007) - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and Acambis plc (London Stock Exchange: ACM) today announced the signing of a research license agreement for PER.C6®. The license agreement allows Acambis to use Crucell's PER.C6® technology for an undisclosed vaccine candidate. Financial details of the agreement were not disclosed.